Kindeva Drug Delivery News and Resources

Kindeva Drug Delivery, through its Meridian Medical Technologies division, has secured a contract valued at up to $129 million to supply DuoDote, an FDA-approved chemical nerve agent antidote, to the U.S. Strategic National Stockpile (SNS). The stockpile is managed by

Kindeva Drug Delivery, a global CDMO and leader in drug delivery solutions, has partnered exclusively with Emervax to co-develop an advanced platform for vaccine administration. This collaboration leverages Kindeva’s solid-coated microneedle array patch and Emervax’s emxRNATM circular RNA vaccine technology,

Kindeva Drug Delivery has announced two major milestones at its Bridgeton, Missouri facility, highlighting the site’s progress in injectable fill-finish capabilities. The company completed its first registration batch on its high-volume vial line, signalling the readiness of the site to

Kindeva Drug Delivery’s Woodbury, MN facility, launched earlier this year, has been successfully inspected and classified by the FDA. The facility, which supports both integrated and stand-alone analytical services for the pharmaceutical, biopharmaceutical, and medical device sectors, is now FDA

Kindeva Drug Delivery, a global provider of drug-device combination products, is investing in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products. This new line will be located in its Loughborough, U.K., facility and will handle

Kindeva Drug Delivery has announced the acquisition of Summit Biosciences Inc., an intranasal drug-delivery CDMO. This strategic move not only adds a new drug-delivery platform to Kindeva’s portfolio but also expands its capabilities across a wider range of complex drug-device combination